{"filings":[{"id":1232276,"accession_number":"0001193125-26-280337","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2026-06-24T12:56:30+00:00","items":["1.02","2.01","3.01","3.03","5.01","5.02","8.01","9.01"],"status":"ready","headline":"Centessa acquired by Eli Lilly for $38/sh plus up to $9/sh CVR","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed June 24, 2026; Centessa became wholly owned subsidiary of Lilly.","Shareholders received $38.00 cash per share plus one CVR worth up to $9.00 on milestones.","All outstanding equity awards cashed out based on $38.00 consideration; CVRs issued.","Centessa terminated its Oxford Finance loan facility and Leerink ATM sales agreement.","CEO, board, and other officers resigned; Christopher Stokes and Kristina Wright appointed directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1027684,"accession_number":"0001193125-26-269474","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2026-06-12T20:15:32+00:00","items":["5.07","8.01"],"status":"ready","headline":"Centessa shareholders approve Lilly acquisition; court sanction hearing June 22","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Shareholders voted 126,653,456 for vs 23,007 against (99.98% of votes cast) to approve the scheme of arrangement.","All seven shareholders of record voted in favor; no shareholder voted against.","Court sanction hearing scheduled for June 22, 2026 at Royal Courts of Justice, London.","Acquisition by Eli Lilly via court-sanctioned scheme expected to close following court approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":609803,"accession_number":"0001193125-26-236933","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2026-05-22T20:15:48+00:00","items":["8.01"],"status":"ready","headline":"HSR waiting period expires for Lilly's acquisition of Centessa; condition satisfied","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Hart-Scott-Rodino waiting period expired at 11:59 p.m. on May 21, 2026, clearing antitrust review.","Acquisition of Centessa by Eli Lilly announced March 31, 2026; remains subject to shareholder vote and court sanction.","Proxy statement filed May 7, 2026; shareholders urged to vote on the scheme of arrangement.","Closing requires approval by Centessa shareholders and sanction by High Court of Justice of England and Wales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109877,"accession_number":"0001193125-26-134656","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Eli Lilly to acquire Centessa for $38/share plus up to $9 in CVRs","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Centessa shareholders receive $38.00 per share cash plus CVRs worth up to $9.00 per share on milestone achievement.","CVR milestones: $2 for first US NDA of ORX750/ORX142 by Dec 31, 2029; $5 for IH approval within 5 yrs; $2 for NT2 approval within 5 yrs.","Supporting shareholders owning ~20% of shares agreed to vote in favor of the scheme.","Transaction expected to close by Sept 30, 2026, extendable to March 31, 2027 for HSR clearance.","Termination fee of ~$63M payable by Centessa under certain circumstances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109876,"accession_number":"0001193125-26-051424","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Centessa finalizes advisory and separation pacts with former CEO Saha","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Saurabh Saha stepped down as CEO on Jan 1, 2026; advisory agreement signed Feb 9, 2026.","Advisory fee of $376/hour for initial six-month term, renewable automatically.","Separation provides vesting of equity through Feb 2, 2026; later equity forfeited.","Subject to Compensation Committee approval, Saha eligible for 100% of 2025 target bonus.","Vested equity exercise window extends to three months after advisory agreement ends."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109875,"accession_number":"0001193125-26-004896","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K/A","filed_at":"2026-01-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Centessa appoints Mario Accardi CEO effective Jan 1, 2026; base salary $600K, target bonus 50%","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Employment Agreement signed Jan 5, 2026; base salary $600,000 per year.","Target annual incentive bonus set at 50% of base salary, first eligible in 2027.","Termination without cause or for good reason (outside 1-yr post-sale): 12 months salary continuation.","Termination within 1 year post-sale event: lump sum of 18 months salary plus 150% target bonus.","Agreement supersedes prior Orexia Ltd employment contract from Jan 2019."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126412,"accession_number":"0001193125-25-315074","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Centessa appoints Mario Accardi as CEO; Saurabh Saha steps down effective Jan 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mario Accardi, President of Orexin Program, becomes CEO on Jan 1, 2026; Saha becomes advisor.","Accardi's base salary set at $600k, target bonus 50%, equity awards target $6M.","Company focuses on orexin franchise; ORX750 registrational program expected to start Q1 2026.","Accardi founded Orexia (acquired by Centessa in 2021) and raised €40M Series A.","Saha resignation not due to any disagreement with company's operations or policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126411,"accession_number":"0001193125-25-292015","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Centessa Pharma enters into $250M ATM equity offering facility with Leerink Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $250M of American Depositary Shares may be sold through Leerink as sales agent.","Commission of 3.0% on gross proceeds; Leerink also receives up to $150K legal expense reimbursement.","No minimum offering amount; net proceeds expected for working capital, capex, and general corporate purposes.","Amends and restates prior sales agreement dated January 27, 2023, with Leerink."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126410,"accession_number":"0001193125-25-278827","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Centessa prices $250M public offering of 11.6M ADSs at $21.50 per ADS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 11,627,907 ADSs at $21.50 each; gross proceeds ~$250M; net proceeds ~$234.4M.","Underwriters granted 30-day option to purchase up to 1,744,186 additional ADSs.","Offering expected to close November 14, 2025; proceeds to fund product development and general corporate purposes.","Existing cash plus net proceeds expected to fund operating expenses into 2028.","Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126409,"accession_number":"0001847903-25-000154","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Centessa reports Q3 net loss of $54.9M; ORX750 Phase 2a meets endpoints in NT1, NT2, IH","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $54.9M in Q3 2025 vs $42.6M in Q3 2024; R&D expenses rose to $41.6M.","Cash and investments $349M as of Sep 30, 2025, expected to fund operations into mid-2027.","ORX750 Phase 2a showed statistically significant improvements on MWT, ESS, and cataplexy rate across NT1, NT2, and IH at low doses.","ORX142 Phase 1 demonstrated rapid onset and differentiated PK; patient studies planned for Q1 2026.","Registrational program for ORX750 expected to start Q1 2026; ORX489 IND-enabling studies ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":15000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143169,"accession_number":"0001847903-25-000133","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Centessa Q2 net loss $50.3M; cash $404.1M; ORX750 Phase 2a data on track for 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $50.3M for Q2 2025, up from $43.8M in Q2 2024; R&D expenses rose to $42.7M.","Cash, cash equivalents and investments totaled $404.1M as of June 30, 2025, expected to fund into mid-2027.","ORX750 Phase 2a CRYSTAL-1 study ongoing; data in NT1, NT2, and idiopathic hypersomnia expected in 2025.","ORX142 Phase 1 first-in-human trial initiated; data in sleep-deprived healthy volunteers expected in 2025.","ORX489 in IND-enabling studies for neuropsychiatric disorders."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":15000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161298,"accession_number":"0001847903-25-000093","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Centessa shareholders approve all proposals at 2025 AGM, including director re-elections","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected Arjun Goyal with 116.9M votes for, 463,793 against; Samarth Kulkarni with 97.7M for, 19.6M against.","Approved KPMG LLP as UK statutory auditors and KPMG LLP (Delaware) as independent auditor for FY2025.","Adopted UK statutory accounts for FY2024; no dividend recommended.","Authorized directors to allot shares up to £133,184 nominal value under Companies Act.","Special resolution passed to empower board to allot equity for cash without pre-emption rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161297,"accession_number":"0001847903-25-000090","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA clears IND for Centessa's ORX142, Phase 1 study in sleep-deprived volunteers planned","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for ORX142, a novel OX2R agonist for neurological/neurodegenerative disorders.","Phase 1 study will evaluate safety, PK, and PD (MWT, KSS) in acutely sleep-deprived healthy adults.","Clinical data from Phase 1 expected this year; study initiation imminent.","ORX142 is second orexin franchise candidate; ORX750 in Phase 2a for narcolepsy/IH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161296,"accession_number":"0001847903-25-000081","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Centessa appoints Raphael Deferiere as Chief Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Raphael Deferiere, CPA, appointed CAO effective May 27, 2025; John Crowley remains CFO.","Base salary of $400,000; annual bonus target 35% of base; option for 165,000 ADSs.","Option vests 25% at one year, then 36 equal monthly installments.","Mr. Deferiere was an Assurance Partner at Ernst & Young LLP (July 2017 – May 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161295,"accession_number":"0001847903-25-000069","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Centessa Q1 net loss $26.1M; cash $424.9M; OX2R agonist pipeline on track for 2025 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $26.1M from $38.0M in Q1 2024, with no product revenue.","Cash, equivalents and investments totaled $424.9M, expected to fund operations into mid-2027.","R&D expenses increased to $33.4M from $22.7M, driven by pipeline advancement.","ORX750 Phase 2a CRYSTAL-1 study ongoing; data from narcolepsy NT1, NT2 and IH anticipated in 2025.","ORX142 first-in-human studies planned in 2025 with data from sleep-deprived healthy volunteers expected."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":15000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179453,"accession_number":"0001847903-25-000049","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Centessa Q4 net loss widens to $111.3M; cash $482M; OX2R pipeline on track for 2025 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $111.3M in Q4 2024 vs $36.8M Q4 2023, full-year loss $235.8M.","R&D expenses $60.9M Q4 2024 included $31.5M one-time charge from SerpinPC discontinuation.","Cash, equivalents and short-term investments $482.2M as of Dec 31, 2024; expected to fund into mid-2027.","ORX750 Phase 2a CRYSTAL-1 data in NT1, NT2, and IH expected in 2025; Phase 1 data showed restored wakefulness.","ORX142 and ORX489 advancing in IND-enabling studies with clinical data expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179452,"accession_number":"0001193125-25-031973","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Centessa licenses LockBody platform to Genmab; $15M upfront, up to $230M per product milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $15M from Genmab; option fees up to $15M for up to three undisclosed targets.","Eligible for ~$230M in development, regulatory, and sales milestones per product plus tiered mid-single-digit royalties.","Genmab to lead all R&D; may combine LockBody technology with Genmab's proprietary antibodies.","LockBody platform enables conditional activation of cell killing in diseased tissue to improve therapeutic index.","Multi-year research period; Genmab can terminate for convenience or on a target-by-target basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179451,"accession_number":"0001847903-25-000003","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Centessa posts corporate slide presentation; no material updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing under Regulation FD discloses current corporate slide presentation as of Jan 8, 2025.","No specific financial or operational updates are included in the filing text.","Slide presentation is available on the company's investor relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196168,"accession_number":"0001847903-24-000192","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Centessa enters up to $200M loan with Oxford Finance, repays $110M Oberland debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $110M term loan funded; proceeds used to repay existing NPA with Oberland Capital in full.","Additional $40M available upon clinical milestone, $50M at lenders' sole discretion; maturity Dec 2029 or Dec 2030 if milestone met.","Interest rate floating at SOFR (floor 3.28%) + 5.00% margin; min 8.28%, max 10.50%.","Loan secured by substantially all assets including IP; minimum cash covenant begins Oct 2026, waived if market cap ≥$1B.","Termination of prior note purchase agreement with Oberland Capital dated Oct 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196167,"accession_number":"0001847903-24-000165","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Centessa discontinues SerpinPC, launches ORX750 Phase 2a, Q3 net loss $42.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Additional interim Phase 1 data for ORX750 in sleep-deprived volunteers showed statistically significant increase in wakefulness at all doses with favorable safety; Phase 2a initiated in NT1, NT2, IH.","Discontinued SerpinPC development after interim analysis; net savings of ~$200M reallocated to OX2R agonist franchise.","Cash $518.4M as of Sept 30, 2024; expected to fund operations into mid-2027.","Completed upsized public offering in Sept 2024 resulting in net proceeds of ~$242.7M.","Advancing ORX142 and ORX489 in IND-enabling studies; clinical data expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212444,"accession_number":"0001193125-24-218828","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Centessa prices upsized $225M ADS offering at $14.75/ADS; net proceeds ~$211M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upsized offering: 15,254,237 ADSs at $14.75/ADS, gross proceeds ~$225M.","Underwriters have 30-day option for additional 2,288,135 ADSs.","Net proceeds ~$211M (or ~$242.7M with full overallotment) to fund product development and corporate.","Company expects existing cash plus net proceeds to fund operations into mid-2027.","Offering expected to close Sept 16, 2024; Goldman Sachs and Leerink Partners lead underwriters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212443,"accession_number":"0001193125-24-216320","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Centessa ORX750 Phase 1 restores normative wakefulness at 2.5 mg, no hepatotoxicity; Phase 2 in Q4","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2.5 mg dose achieved mean sleep latency of 32 min on MWT vs placebo 17 min (p=0.01), restoring normative wakefulness.","No hepatotoxicity, visual disturbances, or common OX2R agonist AEs observed; all AEs mild/transient.","1.0 mg also statistically significant: mean sleep latency 18 min vs placebo 10 min (p=0.04).","Plans to initiate Phase 2 studies in narcolepsy NT1, NT2, and idiopathic hypersomnia in Q4 2024.","Linear PK supports once-daily dosing; systemic exposure dose-proportional."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212442,"accession_number":"0001847903-24-000126","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Centessa Q2 net loss widens to $43.8M; cash $294.8M; ORX750 data expected 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $43.8M vs $24.9M YoY; prior Q2 included $24.1M tax benefit.","Cash $294.8M; funds operations into mid-2026; raised $107.3M net in public offering.","ORX750 Phase 1 initiated; PoC data in sleep-deprived volunteers expected 2H 2024 using MWT.","ORX142 nominated as development candidate; IND-enabling activities underway.","SerpinPC registrational program progressing; PRESent-2 Part 1 interim analysis planned 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231396,"accession_number":"0001847903-24-000095","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Centessa shareholders approve all proposals at 2024 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Francesco De Rubertis, Saurabh Saha, and Mary Lynne Hedley re-elected with 67.8M, 76.4M, and 76.6M votes For respectively.","KPMG LLP (UK) re-appointed as statutory auditor, and KPMG LLP (US) ratified as independent auditor, each with 88.9M For votes.","Advisory resolution to approve directors' remuneration report passed with 76.7M For votes.","Authority to allot shares up to £100,740 nominal and disapply pre-emption rights approved with 68.0M and 64.6M For votes respectively.","All resolutions passed; no dividend recommended for FY2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231395,"accession_number":"0001193125-24-157839","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Centessa appoints John Crowley as CFO, Gregory Weinhoff as Chief Business Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Crowley appointed CFO effective June 10, 2024; replaces Gregory Weinhoff who becomes CBO.","Crowley receives $525k base salary, 40% target annual bonus, and option to purchase 600,000 ADSs.","Crowley previously CFO of Fusion Pharmaceuticals (acquired by AstraZeneca) and Merus, plus finance roles at Charles River, Ironwood, Vertex.","Weinhoff moves from CFO to newly created CBO role; he co-founded Arvelle Therapeutics and led in-licensing of cenobamate.","No family relationships or related-party transactions disclosed between Crowley and the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231394,"accession_number":"0001847903-24-000079","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Centessa Q1 net loss $38M; initiates ORX750 Phase 1, cash runway into mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $38.0M, improved from $50.7M in Q1 2023; R&D expense $22.7M vs $32.8M.","Cash, equivalents, and short-term investments $230.2M as of March 31, plus $107.2M net from April/May ADS offering.","Phase 1 first-in-human trial of ORX750 (narcolepsy) initiated; proof-of-concept data expected 2H 2024.","SerpinPC registrational PRESent-2 interim analysis planned for 2024; Part 1 data to be shared late 2024/early 2025.","LB101 (PD-L1xCD47) Phase 1/2a for solid tumors ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231393,"accession_number":"0001193125-24-108717","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"Centessa prices $100M ADS offering at $9.25; pro forma cash enables runway into mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 10,810,810 ADSs at $9.25/ADS; gross proceeds ~$100M. Close expected Apr 26, 2024.","Net proceeds estimated at $93.5M (or $107.6M if over-allotment exercised).","Underwriters granted 30-day option to purchase up to 1,621,621 additional ADSs.","Preliminary cash, equivalents & ST investments at Mar 31, 2024: $230.2M.","Proceeds to fund product candidate development and general corporate purposes; runway extended into mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231392,"accession_number":"0001847903-24-000069","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA clears IND for Centessa's ORX750 Phase 1 trial in narcolepsy; PoC data expected 2H 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for ORX750, an oral OX2R agonist targeting narcolepsy type 1 (NT1), NT2, and idiopathic hypersomnia.","Phase 1 study includes SAD, MAD, and cross-over PoC using Maintenance of Wakefulness Test and Karolinska Sleepiness Scale in sleep-deprived healthy volunteers.","FDA-set maximum exposure limit significantly exceeds predicted efficacious doses; no impact on planned development.","Dosing to begin imminently; proof-of-concept data anticipated in second half of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249793,"accession_number":"0001847903-24-000052","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Centessa reports Q4 net loss $36.8M; cash $256.5M; SerpinPC and ORX750 milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $36.8M for Q4 2023 vs $43.2M YoY; full-year net loss $151.1M vs $216.2M.","Cash, equivalents and ST investments $256.5M at Dec 31, 2023; plus $9.7M ATM proceeds in Jan 2024; funding into 2026.","SerpinPC PRESent-2 Part 1 interim analysis planned in 2024; Part 1 data at medical conference late 2024/early 2025.","ORX750 IND clearance targeted; clinical proof-of-concept data in sleep-deprived healthy volunteers expected in 2024.","Phase 2a SerpinPC data showed 96% median all-bleed ABR reduction with no thromboembolic events to date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249792,"accession_number":"0001847903-24-000041","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2024-02-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Centessa files 8-K referencing SerpinPC clinical update but no data in exhibit","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Exhibit 99.1 only contains a title slide and standard disclaimers; no numerical results provided.","Presentation is posted on company website but not fully reproduced in the filing.","SerpinPC is an investigational serpin for haemophilia A/B with or without inhibitors.","No financial or guidance changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249791,"accession_number":"0001847903-24-000022","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Centessa Pharmaceuticals posts corporate slide presentation; no material updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["The filing announces a routine corporate slide presentation posted to the company's website.","No financial results, pipeline data, or guidance changes are provided in the filing or exhibit.","The exhibit contains only a disclaimer; the actual slide content is not included in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267255,"accession_number":"0001847903-23-000192","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Centessa SerpinPC Phase 2a Part 5 results: 96% median ABR reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median all-bleed ABR of 1.0, a 96% reduction from prospective baseline of 35.6.","No thromboembolic events or treatment-related sustained D-dimer elevations observed.","Total target joints reduced by 94% (from 53 to 3) by end of Part 5.","Registrational PRESent-2 and PRESent-3 studies for hemophilia B are ongoing.","No SerpinPC-related adverse events reported in Part 5; favorable safety profile."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267254,"accession_number":"0001847903-23-000187","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Centessa Q3 2023 net loss $38.6M; cash $281.3M, SerpinPC data at ASH","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $281.3M as of Sep 30, 2023; expected to fund operations into 2026.","Net loss of $38.6M vs $53.9M in Q3 2022; R&D expense $28.2M, down 23% YoY.","SerpinPC Phase 2a Part 5 data accepted for ASH poster Dec 10; PRESent-2 and PRESent-3 registrational studies ongoing.","ORX750 (OX2R agonist) preclinical data support best-in-class profile for narcolepsy; IND-enabling studies underway, clinical proof-of-concept data planned for 2024.","LockBody platform: LB101 (PD-L1xCD47) Phase 1/2a ongoing; LB206 (PD-L1xCD3) development candidate selected in August."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267253,"accession_number":"0001847903-23-000182","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2023-10-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Centessa presents ORX750 preclinical data; shows potential best-in-class profile for narcolepsy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORX750 potently activates OX2R with EC50 of 0.11 nM and 9,800-fold selectivity over OX1R.","Oral doses as low as 0.1 mg/kg achieved 100% wake time for ≥3 hours and suppressed cataplexy for ≥6 hours in mouse models.","Effects on wake and cataplexy latency maintained for >14 days of dosing.","Clinical proof-of-concept data planned for 2024; IND-enabling studies ongoing.","Preclinical PK profile suggests high, early, and sustained brain exposure in multiple species."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284530,"accession_number":"0001847903-23-000158","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2023-08-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Centessa's oral OX2R agonist ORX750 preclinically reduces cataplexy and promotes wakefulness in narcolepsy mouse model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORX750 is a potent full agonist at human OX2R (EC50=0.11 nM) with >9,800-fold selectivity over OX1R.","In orexin/ataxin-3 narcolepsy mice, ORX750 increased wakefulness and consolidated wakefulness dose-dependently.","At 0.3 mg/kg, latency to sleep was 2.3 h (vs 0.69 h vehicle) and latency to cataplexy was 2.7 h (vs 1.3 h vehicle).","ORX750 also increased EEG gamma power during wakefulness and reduced cataplexy occurrences in active-phase EEG/EMG assays.","Company will present abstract at World Sleep Congress 2023 on October 25, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284529,"accession_number":"0001847903-23-000153","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Centessa Q2 net loss $24.9M; cash $303.6M; SerpinPC registrational study dosing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and short-term investments $303.6M as of June 30; plus $15M ATM gross proceeds in Aug 2023; runway into 2026.","Net loss $24.9M vs $64.7M YoY, including $24.1M tax benefit from valuation allowance release on deferred tax assets.","R&D expenses $33.7M (Q2 2023) vs $53.7M (Q2 2022); G&A $13.3M vs $14.8M.","SerpinPC registrational PRESent-2 study first subject dosed July 2023; FDA Fast Track designation received May 2023.","LB206 (PD-L1xCD3 LockBody) nominated as second development candidate; ORX750 IND-enabling; preclinical data at World Sleep Congress Oct 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284528,"accession_number":"0001847903-23-000150","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Centessa doses first subject in registrational PRESent-2 study for SerpinPC in hemophilia B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dosed first patient in PRESent-2, a Phase 2b registrational study of SerpinPC for hemophilia B without inhibitors.","Interim analysis planned when 36 subjects reach 12 weeks on treatment in Part 1 of the adaptive design.","SerpinPC is a subcutaneously administered APC inhibitor; potential first-in-class therapy for hemophilia B.","Company expects to start registrational PRESent-3 study for hemophilia B with inhibitors later this year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304242,"accession_number":"0001847903-23-000113","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Centessa shareholders approve all proposals at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected directors Carol Stuckley, Brett Zbar, and Mathias Hukkelhoven with over 99.5% support.","KPMG reappointed as UK statutory auditor and independent registered public accounting firm for FY2023.","Adopted UK statutory annual accounts for FY2022; no dividend recommended by directors.","Advisory vote approved directors' remuneration report for FY2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304241,"accession_number":"0001847903-23-000107","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Centessa posts updated corporate presentation; no material new facts disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate slide deck posted to Centessa website on June 9, 2023.","Exhibit 99.1 contains only boilerplate disclaimers and a title slide; substantive content not available.","No financial results, pipeline updates, or guidance changes included in the filing body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304240,"accession_number":"0001847903-23-000099","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Centessa receives FDA Fast Track for SerpinPC in hemophilia B","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track designation to SerpinPC, an investigational inhibitor of activated protein C.","SerpinPC is being developed for hemophilia B, with or without inhibitors.","Fast Track may enable expedited development and rolling review; CEO cites potential first-in-class subcutaneous therapy.","Centessa continues to advance PRESent registrational studies for SerpinPC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304239,"accession_number":"0001847903-23-000095","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Centessa reports Q1 net loss $50.7M, cash $346.2M; advancing SerpinPC, LB101 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $346.2M as of Mar 31, expected to fund operations into 2026; no draw on Oberland credit facility.","Net loss attributable to shareholders $50.7M vs $54.5M YoY; R&D $32.8M (down 11%), G&A $16.1M (up 12%).","SerpinPC registration program for hemophilia B ongoing; PRESent-5 enrolling; PRESent-2/3 dosing expected H2 2023.","LB101 (PD-L1xCD47 LockBody) Phase 1/2a first-in-human trial dosing subjects for solid tumors.","ORX750 (OX2R agonist for narcolepsy) in IND-enabling activities; preclinical data planned at 2023 scientific meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323881,"accession_number":"0001847903-23-000060","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Centessa Q4 net loss $43.2M; cash $393.6M; SerpinPC, LB101, ORX750 progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $393.6M as of Dec 31, 2022; expected to fund operations into 2026.","Net loss attributable to ordinary shareholders $43.2M for Q4 2022 vs $60.8M in Q4 2021.","SerpinPC registrational program for hemophilia B ongoing; PRESent-5 enrolling; PRESent-2/3 dosing expected in 2023.","First subject dosed in Phase 1/2a trial of LB101 (PD-L1xCD47 LockBody) for solid tumors.","ORX750 nominated as product candidate for narcolepsy; preclinical data expected at scientific meeting in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323880,"accession_number":"0001193125-23-017765","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2023-01-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Centessa enters ATM equity offering facility for up to $125M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Sales Agreement with SVB Securities for at-the-market offering of ADS representing ordinary shares.","Company may sell up to $125M of ADS at its discretion; no minimum offering amount required.","SVB Securities to receive 3% commission on gross proceeds; company reimburses legal fees up to $150k.","Net proceeds expected for working capital, capex, and general corporate purposes.","No assurance of any sales; offering terminates upon full sale or agreement termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323879,"accession_number":"0001847903-23-000032","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2023-01-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Centessa gets FDA IND clearance for Phase 1/2a trial of LB101 LockBody candidate for solid tumors","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for LB101, a PD-L1xCD47 bispecific LockBody antibody, for solid tumors.","First LockBody candidate to enter clinic; designed to activate CD47 in tumor microenvironment avoiding systemic toxicity.","CEO Saurabh Saha calls it an important milestone; company plans to advance multiple LockBody candidates.","Phase 1/2a first-in-human trial initiation expected as soon as possible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341857,"accession_number":"0001847903-22-000118","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2022-12-23T23:59:59+00:00","items":["2.04"],"status":"ready","headline":"Centessa obtains waiver for subsidiary name-change default on Note Purchase Agreement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On Dec 22, 2022, Centessa entered a waiver with lenders for an Event of Default under the Oct 1, 2021 Note Purchase Agreement.","Default triggered by failure to provide prior written notice of a subsidiary's legal name change on Nov 22, 2022.","Waiver from Three Peaks Capital Solutions Aggregator Fund and Cocoon SA LLC (Oberland Capital affiliate) avoids loan acceleration and penalties.","Without waiver, lenders could have accelerated the loan under the Note Purchase Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341856,"accession_number":"0001847903-22-000115","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Centessa reports 93% bleed reduction with SerpinPC in 18-month OLE; no safety signals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median all-bleeds ABR reduced 93% at 1.2 mg/kg every 2 weeks; median ABR 2.2, 7 of 21 subjects zero bleeds.","No thromboembolic events or treatment-related D-dimer elevations over 18 months; no SerpinPC-related AEs.","Pivotal program advancing: PRESent-5 observation study to start in coming weeks; interventional studies planned for 2023.","Total exposure over 40 patient-years across multiple dosing regimens; sustained safety and tolerability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341855,"accession_number":"0001847903-22-000082","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Centessa Q3 net loss $53.9M, cash $444.8M; SerpinPC and LB101 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $53.9M in Q3 2022 vs $40.2M in Q3 2021; R&D spend $36.7M vs $25.9M.","Cash $444.8M provides runway into 2026; no additional draw on Oberland facility.","SerpinPC pivotal program: PRESent-5 observational study starting Q4 2022; Phase 2a OLE data at ASH Dec 10.","LB101 IND submission for PD-L1xCD47 bispecific on track for late 2022.","SerpinPC granted FDA Orphan Drug Designation in September 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341854,"accession_number":"0001847903-22-000071","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2022-10-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Centessa CMO Javad Shahidi departs; Antoine Yver assumes responsibilities effective Oct 14, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Javad Shahidi mutually agreed to depart; last day Oct 14, 2022.","Departure not due to any disagreement regarding operations, policies, or practices.","Chairman of Development Antoine Yver (30+ yrs drug dev) assumes all CMO responsibilities effective Oct 14.","Dr. Yver led approvals for 11 drugs including Tagrisso, Lynparza, Enhertu; prior roles at Daiichi Sankyo and AstraZeneca."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341853,"accession_number":"0001193125-22-258932","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2022-10-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Centessa files corrected Articles of Association; no change to share structure or rights","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corrected Articles of Association adopted May 2021, effective June 2021, filed with UK Registrar.","Articles authorize issuance of unlimited ordinary shares and unlimited deferred shares.","Filing is procedural; no impact on business operations or financial results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358704,"accession_number":"0001847903-22-000053","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2022-09-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Centessa furnishes corporate presentation; no specific financial or operational updates","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted to Investor section of centessa.com as of September 12, 2022.","No earnings, guidance, pipeline data, or other material disclosures included in the filing.","Presentation contains standard corporate overview and forward-looking disclaimers only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":6153571049.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-09-12T23:59:59+00:00|358704"}